Objective
ACE inhibitors are renoprotective in adults with chronic renal failure (CRF), but of unproven usefulness in children. In a randomised trial in 350 CRF children we will address if ACE inhibition is efficacious in slowing CRF progression in acquired and congenital nephropathies, if progression can be additionally influenced by intensified antihypertensive treatment achieving low-normal blood pressure, and which factors determine CRF progression and/or its susceptibility to ACE inhibition. Potential effects of renin-angiotensin system and PAI-l gene polymorphisms, mutations in genes defining glomerular structure or causing renal hypo/dysplasia, renal endothelnr-l turnover, plasma homocysteine and apolipoprotein phenotypes will be assessed. The cardiovascular consequences of childhood-onset CRF and renoprotective pharmacotherapy will be addressed by carotid ultrasound, echocardiography and 24-hour blood pressure monitoring.
Fields of science
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
69115 HEIDELBERG
Germany
See on map
Participants (27)
10126 TORINO (TURIN)
See on map
35128 PADOVA
See on map
20122 MILANO
See on map
34303 ISTANBUL
See on map
04 736 WARSZAWA
See on map
06100 ANKARA
See on map
30625 HANNOVER
See on map
67098 STRASBOURG
See on map
4202-451 PORTO
See on map
141 86 HUDDINGE
See on map
10117 BERLIN
See on map
75743 PARIS
See on map
34390 ISTANBUL
See on map
16148 GENOVA
See on map
55101 MAINZ
See on map
00165 Roma
See on map
35043 MARBURG
See on map
70 954 SZCZECIN
See on map
1083 BUDAPEST
See on map
04129 LEIPZIG
See on map
45122 ESSEN
See on map
8032 ZURICH
See on map
20246 HAMBURG
See on map
150 06 PRAHA 5
See on map
11000 BELGRADE
See on map
01330 ADANA
See on map
35040 BORNOVA
See on map